Subscription business model

United States Dating Apps Market Report 2023: Analysis By Age Group, Gender, Subscription Plan - Market Size, Insights, & Competition 2018-2022 & 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 3, 2023
Women, Consumer, Men, Apps, Applications, Technology, BLK, Internet, Culture, Marriage, OkCupid, EHarmony, USD, Consultant, Competition, Match.com, Subscription business model, COVID-19, Spark Networks, Personality, Badoo, Growth, Match Group, Social media, Online shopping, Video game, Chispa Summit Formation, Bumble

The "United States Dating Application Market (2023 Edition) - Analysis By Age Group (18-25, 25-34, 35-50, >50 Years), Gender, By Subscription Plan: Market Size, Insights, Competition, Covid-19 Impact and Forecast (2023-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Dating Application Market (2023 Edition) - Analysis By Age Group (18-25, 25-34, 35-50, >50 Years), Gender, By Subscription Plan: Market Size, Insights, Competition, Covid-19 Impact and Forecast (2023-2028)" report has been added to ResearchAndMarkets.com's offering.
  • The United States Dating Application Market is expected to generate USD 5057.82 million by the end of 2028, up from USD 3378.58 million in 2021.United States Dating Application Market is expected to expand at a CAGR of 6% during 2023-2028.
  • Popular and trusted dating apps like Tinder, Bumble, and Badoo are key players driving market expansion.
  • Broadband internet accessibility and the mainstream acceptance of online dating are additional factors that contribute to market growth.

NETSOL Technologies Reports Fiscal Fourth Quarter and Year End 2023 Financial Results

Retrieved on: 
Friday, September 22, 2023
Amazon Web Services, Software as a service, Quarter, API, Web browser, GAAP, Target, NetSol Technologies, Subscription business model, EBITDA, Growth, Development, Total, Music, Video game, Cryptocurrency, Bank, Cloud

Gross profit for the fourth quarter of fiscal 2023 was $4.8 million (or 35.0% of net revenues), consistent with $4.8 million (or 35.6% of net revenues) in the fourth quarter of fiscal 2022.

Key Points: 
  • Gross profit for the fourth quarter of fiscal 2023 was $4.8 million (or 35.0% of net revenues), consistent with $4.8 million (or 35.6% of net revenues) in the fourth quarter of fiscal 2022.
  • Operating expenses for the fourth quarter of fiscal 2023 were $7.7 million (or 56.0% of sales) compared to $6.4 million (or 47.0% of sales) for the fourth quarter of fiscal 2022.
  • On a constant currency basis, operating expenses for the fourth quarter of fiscal 2023 increased to $9.0 million (or 63.9% of sales on a constant currency basis).
  • On a constant currency basis, GAAP net loss attributable to NETSOL for the fourth quarter of fiscal 2023 totaled $(7.8 million) or $(0.69) per diluted share.

Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program

Retrieved on: 
Monday, September 18, 2023
CET, Diabetes, DME, Tranche, Paratriathlon, Advertiser-funded programming, EUR, Subscription business model, Patient, Brussels Stock Exchange, Pharmaceutical industry

On September 15, 2023, the Company issued 40 convertible bonds with a value of EUR 1 million to Atlas.

Key Points: 
  • On September 15, 2023, the Company issued 40 convertible bonds with a value of EUR 1 million to Atlas.
  • This Tranche is the first installment of the EUR 3.5 million in unconditional funding agreed with Atlas allowing the Company to reach the topline data of the Phase 2, Part B of the KALAHARI trial, which is expected by the end of 2023.
  • Under the Funding Program, Atlas has committed to 20 million in funding over a 24-month period, of which it has now subscribed to EUR 9 million (leaving a remainder of EUR 11 million of which the conditions are waived for EUR 2.5 million).
  • Tom Graney, CEO of Oxurion, said: “Given Atlas’s steadfast support, Oxurion is confident of reaching the topline data from the KALAHARI trial without the need for additional capital.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Monday, September 18, 2023
Agreement, Capital commitment, Cayman, Term Asset-Backed Securities Loan Facility, Atlas, Disclosure, USD, EUR, Subscription business model, SRS, Brussels Stock Exchange, Capital, Security (finance), Limited

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,667,771,604 outstanding ordinary shares carrying voting rights (compared to 2,551,311,977 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Oxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023

Retrieved on: 
Monday, September 11, 2023
CFA, Privacy and Civil Liberties Oversight Board report on mass surveillance, DME, Diabetic retinopathy, Atlas, Paratriathlon, Prospectus, Loan agreement, Subscription business model, Patient, Brussels Stock Exchange, Convertible, Issuer, Loan, Disease, Security (finance), Credit

Atlas has agreed to waive the market capitalization and liquidity conditions for up to €3.5 million in mandatorily convertible bonds.

Key Points: 
  • Atlas has agreed to waive the market capitalization and liquidity conditions for up to €3.5 million in mandatorily convertible bonds.
  • The amount of the monthly payments, which will be made mid-month, shall not be reduced; rather, the Loan Agreement shall be repaid more quickly.
  • Tom Graney, CFA, CEO of Oxurion, said: “We greatly appreciate the vote of confidence that our partners, Atlas and Kreos/Pontifax, have shown Oxurion through these financial commitments enabling Oxurion to progress the Phase 2, Part B KALAHARI trial of THR-149 in Diabetic Macular Edema (DME), to the topline results later this year.
  • We are eager to share the expected topline data from the KALAHARI trial of THR-149, which holds the exciting potential of addressing this large unmet need and attractive market later this year.”

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Thursday, September 7, 2023
Agreement, Capital commitment, Cayman, Term Asset-Backed Securities Loan Facility, Atlas, Disclosure, USD, EUR, Subscription business model, SRS, Brussels Stock Exchange, Capital, Security (finance), Limited

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,551,311,977 outstanding ordinary shares carrying voting rights (compared to 2,444,979,274 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Friday, September 1, 2023
Agreement, Capital commitment, Cayman, Term Asset-Backed Securities Loan Facility, Atlas, Disclosure, USD, EUR, Subscription business model, SRS, Brussels Stock Exchange, Capital, Security (finance), Limited

Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,444,979,274 outstanding ordinary shares carrying voting rights (compared to 2,278,608,378 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by the Company Once Shareholder Approvals Have Been Obtaine

Retrieved on: 
Thursday, August 31, 2023
Call option, Acquisition, Used note, Toronto Stock Exchange, Loan, Loan agreement, Second, Minority, IGX, Related, Customary international law, National instrument, Offering, Useful conversions and formulas for air dispersion modeling, TSX, Security (finance), Multilateral, Bankruptcy, Exercise, Constitutional right, Condition subsequent, Berlin, Call, Government patent use (United States), MI, Option style, CDN, Shareholder, Sale, Initial, Subscription business model, Life insurance, Unit, Share (finance), Warrant, Note, Corporation

atai, a significant shareholder and partner of the Company, subscribed, on the date hereof, for 2,220 US Units for aggregate gross proceeds to the Company of US$2,220,000 (the “Initial atai Proceeds”).

Key Points: 
  • atai, a significant shareholder and partner of the Company, subscribed, on the date hereof, for 2,220 US Units for aggregate gross proceeds to the Company of US$2,220,000 (the “Initial atai Proceeds”).
  • The Corporation will seek to obtain the Shareholder Approvals at an upcoming special meeting of Shareholders to be held as soon as practicable after the date hereof.
  • An early warning report will be filed under the Company’s profile on the SEDAR+ website at www.sedarplus.ca.
  • This press release does not constitute an offer of securities for sale in the United States.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Friday, August 25, 2023
Agreement, Capital commitment, Cayman, Term Asset-Backed Securities Loan Facility, Atlas, Disclosure, USD, EUR, Subscription business model, SRS, Brussels Stock Exchange, Capital, Security (finance), Limited

Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,278,608,378 outstanding ordinary shares carrying voting rights (compared to 2,153,190,318 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Wednesday, August 23, 2023
Agreement, Capital commitment, Cayman, Term Asset-Backed Securities Loan Facility, Atlas, Disclosure, USD, EUR, Subscription business model, SRS, Brussels Stock Exchange, Capital, Security (finance), Limited

Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,153,190,318 outstanding ordinary shares carrying voting rights (compared to 2,030,138,637 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.